Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

NCT01593410 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01593410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01593410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-Label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
August 1, 2010
Completion date
January 3, 2013
Enrollment
194 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma